Robert J. More - Sep 14, 2021 Form 3 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role: Director, 10%+ Owner
Signature: /s/ John Healy, Attorney-in Fact
Stock symbol: TYRA
Transactions as of: Sep 14, 2021
Transactions value $: $0
Form type: 3
Date filed: 9/14/2021, 09:19 PM
Previous filing: Jul 19, 2021
Next filing: Sep 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TYRA	Common Stock						113K	Sep 14, 2021	See footnotes	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TYRA	Series A Preferred Stock							Sep 14, 2021	Common Stock	3.15M	$0.00	See footnotes	F1, F2
holding	TYRA	Series B Preferred Stock							Sep 14, 2021	Common Stock	663K	$0.00	See footnotes	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.
F2	The shares of Series A Preferred Stock and Series B Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1-for-2.5974. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1-for-2.5974. The Series A Preferred Stock and Series B Preferred Stock has no expiration date.

Content

These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.

The shares of Series A Preferred Stock and Series B Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1-for-2.5974. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1-for-2.5974. The Series A Preferred Stock and Series B Preferred Stock has no expiration date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney